Experience

icometrix

• Belgium
• Hospitals and Health Care
• 1 - 100 Employee

• President- Board of Directors

  • Jul 2021 - Present



Catalyst Clinical Research

• United States
• Pharmaceutical Manufacturing
• 300 - 400 Employee

• Member Board Of Directors

  • Mar 2019 - Present



Warner Consulting, LLC

• CEO and Founder

  • Jan 2018 - Present



Clinical Trial Concepts, LLC

• CEO and Founder

  • Jan 2018 - Present



Wake Forest University

• United States
• Higher Education
• 700 & Above Employee

• Advisory Board, Center for Private Business

  • Jul 2016 - Present

  The Wake Forest University Center for Private Business enables privately owned businesses to achieve their dreams for their business, family, employees, community, and stakeholders by providing access to industry leaders, resources, networks, students, and education. The Wake Forest University Center for Private Business enables privately owned businesses to achieve their dreams for their business, family, employees, community, and stakeholders by providing access to industry leaders, resources, networks, students, and education.



University of North Carolina at Chapel Hill

• United States
• Higher Education
• 700 & Above Employee

• Adjunct Associate Professor

  • Dec 2013 - Present



Predictive Oncology

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Member, Board of Scientific Advisors

  • Sep 2018 - Feb 2022

  Precision Therapeutics is focused on applying artificial intelligence to personalized medicine and drug discovery. This business has launched with Precision Therapeutics' investment in Helomics Corporation, a precision medicine company and integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. As a Member of Precision Therapeutics’ Scientific Advisory Board, I work closely with senior management team to advance the company's growth strategy in this market.http://www.precisiontherapeutics.com



Global Specimen Solutions, Inc.

• Founder and CEO

  • Jul 2013 - Dec 2017

  As founder and CEO of Global Specimen Solutions, Inc., Dr. Warner led the innovation and creation of a new CRO market space for clinical trial monitoring of biospecimen movement around the world. Dr. Warner filed 3 patents, brought 5 products to market and oversaw global installation of expert operations to monitor specimen chain-of-custody for global pharmaceutical clinical trials. In December 2017, Covance purchased GSS and made this service part of their global suite of clinical trial solutions.Dr. Warner provided intellectual leadership and business oversight to bring 5 informatics products to market with associated operational practices in just 3 years. These include GlobalCODE(R)- an integrated informatics solution for specimen, informed consent, and assay tracking, snapTRACK(R)- a patented mobile app solution for tracking biospecimen chain-of-custody from the collection site, LabCODE(TM)- a novel cloud-based LIMS solution that integrates with global tracking from GlobalCODE(R) to provide ongoing tracking for local laboratories, GSS OPS- a data curation and reconciliation tool for managing disparate data sources for clinical trials, and DeToxify(TM)- a novel data loading/curation/cleaning tool to manage in-life data for clinical trials.Dr. Warner also filed patents and trademarks for the creation of BitSpecimen(TM) and BitGenome(TM)- block-chain based technologies to allow secure releases of specimen and genomic related specimen data for research purposes.Dr. Warner led successful Series A funding for Global Specimen Solutions, Inc. and led the company to high year-upon-year growth while driving market change for standards of how clinical data is managed. Dr. Warner led the company to a successful transaction with a public company in December of 2017.



Gentris | A CGI Company

• United States
• Biotechnology
• 1 - 100 Employee

• CEO and President, Director, Gentris Board of Directors

  • Jul 2013 - Jul 2014

  As CEO and President of Gentris, Amelia led the successful corporate turnaround strategy bringing the company to new competitive advantage. Under her tenure, Gentris Shanghai was commercially launched, GenTrax (a novel bioinformatics laboratory solution) was released, Biobanking was added as a fully focused business vertical, and financial strategies were implemented to turnaround corporate financial success. This corporate overhaul transformed the future projections for Gentris and led to successful acquisition of Gentris by a public company in 2014.



Merck

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Director, Head Global Clinical Pharmacogenomics

  • Jun 2006 - Jul 2013

  Head, Clinical Pharmacogenomics and Clinical Specimen ManagementLate Stage DevelopmentBuilt and managed a highly functioning team responsible for corporate-wide clinical pharmacogenomic strategy in clinical development programs, human specimen research policy and procedures for Merck, oversight for a 3.5 million + specimen biorepository, and was responsible for the team that built/innovated the most expansive inventory management/knowledge management system in the industry for biomarker research.



Pfizer

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Assistant Director, Global Medical Affairs

  • 2005 - 2006



Children's Hospital of Philadelphia

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Head, Clinical Pharmacogenomics

  • 2001 - 2005



St. Jude Children's Research Hospital - ALSAC

• United States
• Non-profit Organizations
• 700 & Above Employee

• Pharmacogenomics Fellow

  • 1999 - 2001

  Research focused on pharmacogenomics of anticancer drugs.

• Resident, Pediatric Oncology Pharmacotherapy

  • Jul 1998 - Jul 1999